Study Of TYZEKA with Compensated Chronic Hepatitis B Virus Infection
The purpose of this study is to estimate the proportion of patients who achieve non-detectable HBV DNA in black/Caribbean/African Americans and Hispanic/Latinos with compensated chronic hepatitis B during 24 weeks of treatment with telbivudine.
You may be eligible to participate in this study if you:
- Have documented compensated chronic Hepatitis B
- Are black Caribbean, African American and/or Hispanic/Latino
This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.